Fibrates and coronary risk reduction.
Many medications are currently available to correct lipoprotein abnormalities when lifestyle measures alone are not sufficient. No single agent or class of agents is able to correct all of the lipoprotein abnormalities. This paper reviews the role of one class, the fibrates, in the management of lipid disorders and summarizes the clinical trial information relating to their impact on coronary artery disease.
Steiner
George
G
Division of Endocrinology and Metabolism, Toronto General Hospital, 200 Elizabeth Street, University of Toronto, Toronto, Ontario, Canada M5G 2C4. george.steiner@uhn.on.ca
D018680:Cholinergic Antagonists / Q000627:therapeutic use*; D002995:Clofibric Acid / Q000627:therapeutic use*; D003324:Coronary Artery Disease / Q000453:epidemiology* / Q000517:prevention & control*; D006801:Humans; D012307:Risk Factors
D018680:Cholinergic Antagonists; D002995:Clofibric Acid